Ensysce Biosciences CEO Lynn Kirkpatrick released a 2024 shareholder letter detailing the company's progress in 2023, focusing on the development of their lead analgesic PF614 and PF614-MPAR, both designed to treat severe pain with overdose protection. The company presented clinical data at various scientific meetings, completed clinical trials, and prepared for regulatory submissions to the FDA. They also engaged Alacrita Consulting for business development and explored a partnership with OncoZenge AB for a non-opioid pain treatment. Ensysce raised $12 million in financing to support their clinical programs and is preparing for FDA discussions to advance PF614 and PF614-MPAR through the 505(B)(2) regulatory pathway.